Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
In this proposed study the investigators will combine gemcitabine and cisplatin with
talazoparib to determine the recommended Phase 2 dose (RP2D) of this combination regimen.
After determination of the RP2D patients with lung cancer whose tumors carry molecular
alterations in DNA repair pathway genes will be enrolled to an expansion cohort to determine
anti-tumor efficacy. Tissue samples of patients with confirmed partial response, complete
response, and non-responders will be obtained for whole exome, and transcriptome sequencing
to characterize the genetic alterations associated with response to therapy.